1-4 of 4
M. Beth McCarville
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma

Free
Sara M. Federico, M. Beth McCarville, Barry L. Shulkin, Paul M. Sondel, Jacquelyn A. Hank, Paul Hutson, Michael Meagher, Aaron Shafer, Catherine Y. Ng, Wing Leung, William E. Janssen, Jianrong Wu, Shenghua Mao, Rachel C. Brennan, Victor M. Santana, Alberto S. Pappo, Wayne L. Furman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (21): 6441–6449.
https://doi.org/10.1158/1078-0432.CCR-17-0379
Published: 31 October 2017
View articletitled, A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma
Open the PDF for A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

Available to Purchase
Fariba Navid, Sharyn D. Baker, M. Beth McCarville, Clinton F. Stewart, Catherine A. Billups, Jianrong Wu, Andrew M. Davidoff, Sheri L. Spunt, Wayne L. Furman, Lisa M. McGregor, Shuiying Hu, John C. Panetta, David Turner, Demba Fofana, Wilburn E. Reddick, Wing Leung, Victor M. Santana
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 236–246.
https://doi.org/10.1158/1078-0432.CCR-12-1897
Published: 02 January 2013
View articletitled, Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors
Open the PDF for Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors in another window
Journal Articles

Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy

Available to Purchase
Paxton V. Dickson, John B. Hamner, Thomas L. Sims, Charles H. Fraga, Catherine Y.C. Ng, Surender Rajasekeran, Nikolaus L. Hagedorn, M. Beth McCarville, Clinton F. Stewart, Andrew M. Davidoff
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (13): 3942–3950.
https://doi.org/10.1158/1078-0432.CCR-07-0278
Published: 02 July 2007
View articletitled, Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy
Open the PDF for Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy in another window
Journal Articles

Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors

Available to Purchase
Lars M. Wagner, Kristine R. Crews, Lisa C. Iacono, Peter J. Houghton, Christine E. Fuller, M. Beth McCarville, Robert E. Goldsby, Karen Albritton, Clinton F. Stewart, Victor M. Santana
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 840–848.
https://doi.org/10.1158/1078-0432.CCR-03-0175
Published: 10 February 2004
View articletitled, Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors
Open the PDF for Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors in another window